A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
PHASE3CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
September 30, 2012
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
Conditions
HIV
Interventions
DRUG
tenofovir/emtricitabine/rilpivirine
Trial Locations (1)
SW10 9TH
St Stephen's AIDS Trust, London
All Listed Sponsors
lead
St Stephens Aids Trust
OTHER
NCT01701882 - A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine | Biotech Hunter | Biotech Hunter